You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

p16, CDKN2A

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor, CDKN2A, NSCLC Trial (Milademetan, Atezolizumab)

Withdrawn
  • Advanced Solid Tumor
  • +9 more
  • (no location specified)
Oct 16, 2023

CDKN2A-p16 Positive, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell

Recruiting
  • CDKN2A-p16 Positive
  • +5 more
  • Tucson, Arizona
    The University of Arizona Medical Center-University Campus
Mar 7, 2022

Head Neck Cancer, Advanced Cancer, Metastatic Cancer Trial in Bordeaux, Lyon, Nice (Abemaciclib)

Recruiting
  • Head and Neck Cancer
  • +2 more
  • Bordeaux, France
  • +2 more
Jul 22, 2022

Oropharyngeal Cancer, Squamous Cell Carcinoma of the Oropharynx Trial in Ann Arbor (procedure, combination product, other,

Recruiting
  • Oropharyngeal Cancer
  • Squamous Cell Carcinoma of the Oropharynx
  • Surgery
  • +3 more
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
May 30, 2023

Oropharynx Cancer Trial in Philadelphia (Radiation therapy (5 days for 7 weeks), Radiation therapy (5 days for 6 weeks),

Recruiting
  • Oropharynx Cancer
  • Radiation therapy (5 days for 7 weeks)
  • +2 more
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Apr 5, 2023

HPV-unrelated Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (Palbociclib, Cetuximab)

Recruiting
  • HPV-unrelated Head and Neck Squamous Cell Carcinoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Apr 7, 2022

Prostate Cancer Trial in Beijing (68Ga-P16-093, 68Ga-PSMA-11)

Recruiting
  • Prostate Cancer
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Nov 1, 2022

Prostate Cancer Trial in Beijing (68Ga-PSMA-617, 68Ga-P16-093)

Recruiting
  • Prostate Cancer
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Aug 4, 2022

GBM, Glioblastoma, Brain Tumor Trial in Dallas (Abemaciclib, Bevacizumab)

Active, not recruiting
  • GBM
  • +3 more
  • Dallas, Texas
    UT Southwestern Medical Center
Jan 23, 2022

Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-P16-093, 18F-FDG)

Recruiting
  • Clear Cell Renal Cell Carcinoma
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Jun 21, 2022

People Who Have Genetic Changes and Features of Autism: Simons

Recruiting
  • 16P11.2 Deletion Syndrome
  • +184 more
    • New York, New York
    • +1 more
    Jan 6, 2023

    Cyclin-dependent Kinase Inhibitor 2A on Labor-related Signals

    Not yet recruiting
    • Preterm Labor
      • (no location specified)
      May 9, 2023

      ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma Trial

      Recruiting
      • ENSAT Stage I Adrenal Cortex Carcinoma
      • +2 more
      • Ann Arbor, Michigan
      • +3 more
      Dec 13, 2022

      Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally

      Recruiting
      • Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
      • +5 more
      • Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101
      • Pembrolizumab
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Jan 4, 2023

      Oropharyngeal Squamous Cell Carcinoma Trial in Philadelphia (adjuvant radiotherapy)

      Recruiting
      • Oropharyngeal Squamous Cell Carcinoma
      • adjuvant radiotherapy
      • Philadelphia, Pennsylvania
      • +2 more
      Feb 2, 2023

      Protein P16 Expression in Ovarian Germ Cell Tumors.

      Completed
      Has Results
      • Ovarian Neoplasms
      • +2 more
      • p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267)
      • Ki67 antibody (DAKO) for malignant cases only
      • Assiut, Egypt
        Assiut University
      Aug 12, 2021

      Alzheimer Trial in Baltimore ([18F]P16-129)

      Completed
      • Alzheimer Disease
      • Baltimore, Maryland
        Johns Hopkins Medical Institutions
      Jul 16, 2021

      Pulmonary Sarcoidosis Trial (XTMAB-16 or Placebo)

      Not yet recruiting
      • Pulmonary Sarcoidosis
      • XTMAB-16 or Placebo
      • (no location specified)
      May 25, 2023

      Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV

      Recruiting
      • Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
      • +28 more
      • San Francisco, California
        University of California, San Francisco
      Dec 16, 2022

      Early Breast Cancer Three Years of More Post Primary Treatment

      Recruiting
      • Breast Cancer
      • Exercise Recall Patient Reported Outcomes
      • +10 more
      • Chapel Hill, North Carolina
        University of North Carolina
      Jun 21, 2023

      Clinical Stage II HPV-Mediated (p16-pos) Oropharyngeal Carcinoma, Clinical Stage III HPV-Mediated (p16-pos) Oropharyngeal

      Not yet recruiting
      • Clinical Stage II HPV-Mediated (p16-pos) Oropharyngeal Carcinoma
      • +15 more
      • Best Practice
      • +9 more
      • Scottsdale, Arizona
        Mayo Clinic in Arizona
      Aug 23, 2022

      Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive)

      Recruiting
      • Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
      • +10 more
      • Intensity-Modulated Radiation Therapy
      • +4 more
      • Houston, Texas
        M D Anderson Cancer Center
      Nov 8, 2022

      Type 2 Diabetes Trial (HRS-7535, Placebo)

      Not yet recruiting
      • Type 2 Diabetes
      • (no location specified)
      Feb 26, 2023

      HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))

      Not yet recruiting
      • HER2-positive Breast Cancer
      • Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
      • (no location specified)
      Jul 20, 2023

      HPV-Related Squamous Cell Carcinoma, HNSCC Trial in London (VB10.16, Pembrolizumab)

      Not yet recruiting
      • HPV-Related Squamous Cell Carcinoma
      • HNSCC
      • London, United Kingdom
        East and North Hertfordshire NHS Trust Mount Vernon Hospital
      Aug 24, 2023